May 7
Funding Australia’s Future Economy: CUREator Deploys $7.21 Million to Propel local Life Sciences Potential
Read moreBrandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areVaxxas' proprietary Nanopatch™ technology is a needle-free vaccine delivery solution
View ProjectDeveloping a new class of therapeutics that enhance the function of beneficial proteins
View ProjectTargeting long non-coding RNAs for next generation cancer therapies
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectThe Garvan Institute of Medical Research is one of Australia's premier medical research institutes. We see a future where everyone lives a longer, healthier life.
ViewCallaghan Innovation is the New Zealand government’s innovation agency, helping businesses succeed through technology. We act as a gateway to innovation in New Zealand by connecting the rest of the world to Kiwi companies, research institutes, incubators, universities and commercialisation offices.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreFunding Australia’s Future Economy: CUREator Deploys $7.21 Million to Propel local Life Sciences Potential
Read moreENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 – a First-in-Class Antiviral Innate Immunomodulator
Read morePathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic
Read moreAzura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases
Read more